Diagnostic Criteria in Polycystic Ovary Syndrome

Seminars in Reproductive Medicine

Volumn 21, Issue 3, 2003, Pages 267-275

  Legro, Richard S ^a,b  

^a PENN STATE MILTON S HERSHEY MEDICAL CENTER   (United States)

^b PENN STATE COLLEGE OF MEDICINE   (United States)

Author keywords

Androgen excess; Anovulation; Insulin resistance; Ultrasonography

Indexed keywords

INSULIN; TESTOSTERONE;

ANOVULATION; CLINICAL FEATURE; ECHOGRAPHY; EVIDENCE BASED MEDICINE; FEMALE; HUMAN; HYPERANDROGENISM; INCIDENCE; INSULIN RESISTANCE; LONG TERM CARE; OVARY POLYCYSTIC DISEASE; OVULATION; PRACTICE GUIDELINE; PREVALENCE; REVIEW; TESTOSTERONE BLOOD LEVEL;

ANOVULATION; BLOOD GLUCOSE; FASTING; FEMALE; GLUCOSE TOLERANCE TEST; GONADOTROPINS; HUMANS; HYPERANDROGENISM; INSULIN; INSULIN RESISTANCE; OVARY; POLYCYSTIC OVARY SYNDROME;

EID: 0142030696     PISSN: 15268004     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2003-43304     Document Type: Review

References (67)

1. Zawadski JK, Dunaif A. Diagnostic criteria for polycystic ovary syndrome: towards a rational approach. In: Dunaif A, ed. Polycystic Ovary Syndrome. Boston: Blackwell Scientific; 1992:377-384
2. Franks S. Polycystic ovary syndrome [published erratum appears in N Engl J Med 1995;333:1435]. N Engl J Med 1995;333:853-861
3. Franks S. Polycystic ovary syndrome [published erratum appears in N Engl J Med 1995;333:1435]. N Engl J Med 1995;333:853-861
4. Lobo RA. A disorder without identity: "HCA," "PCO," "PCOD,""PCOS,""SLS". What are we to call it? [editorial]. Fertil Steril 1995;63:1158-1160
5. Raj SG, Thompson IE, Berger MJ, Talert LM, Taymor ML. Diagnostic value of androgen measurements in polycystic ovary syndrome. Obstet Gynecol 1978;52:169-171
6. Adams J, Polson DW, Franks S. Prevalence of polycystic ovaries in women with anovulation and idiopathic hirsutism. Br Med J 1986;293:355-359
7. Legro RS, Finegood D, Dunaif A. A fasting glucose to insulin ratio is a useful measure of insulin sensitivity in women with polycystic ovary syndrome. J Clin Endocrinol Metab 1998;83:2694-2698
8. Rebar R, Judd HL, Yen SS, Rakoff J, Vandenberg G, Naftolin F. Characterization of the inappropriate gonadotropin secretion in polycystic ovary syndrome. J Clin Invest 1976;57:1320-1329
9. Keettel WC, Bradbury JT, Stoddard FJ. Observations on the PCO syndrome. Am J Obstet Gynecol 1957;73:954-965
10. McArthur JW, Ingersall FM, Worcester J. The urinary excretion of interstitial cell and follicle-stimulating hormone activity by women with diseases of the reproductive system. J Clin Endocrinol Metab 1958;18:1202-1205
11. Yen SS, Vela P, Rankin J. Inappropriate secretion of follicle-stimulating hormone and luteinizing hormone in polycystic ovarian disease. J Clin Endocrinol Metab 1970;30:435-442
12. Robinson S, Rodin DA, Deacon A, Wheeler MJ, Clayton RN. Which hormone tests for the diagnosis of polycystic ovary syndrome? Br J Obstet Gynaecol 1992;99:232-238
13. Arroyo A, Laughlin GA, Morales AJ, Yen SS. Inappropriate gonadotropin secretion in polycystic ovary syndrome: influence of adiposity. J Clin Endocrinol Metab 1997;82:3728-3733
14. Taylor AE, McCourt B, Martin KA, Anderson EJ, Adams JM, Schoenfeld DH. Determinants of abnormal gonadotropin secretion in clinically defined women with polycystic ovary syndrome. J Clin Endocrinol Metab 1997;82:2248-2256
15. Legro RS, Kunselman AR, Dodson WC, Dunaif A. Prevalence and predictors of risk for type 2 diabetes mellitus and impaired glucose tolerance in polycystic ovary syndrome: a prospective, controlled study in 254 affected women. J Clin Endocrinol Metab 1999;84:165-169
16. Lobo RA, Shoupe D, Chang SP, Campeau J. The control of bioactivc luteinizing hormone secretion in women with polycystic ovary syndrome. Am J Obstet Gynecol 1984;148:423-428
17. Fauser BC, Pache TD, Hop WC, de Jong FH, Dahl KD. The significance of a single serum LH measurement in women with cycle disturbances: discrepancies between immunoreactive and bioactive hormone estimates. Clin Endocrinol (Oxf) 1992;37:445-452
18. Polson DW, Adams J, Wadsworth J, Franks S. Polycystic ovaries: a common finding in normal women. Lancet 1988;1:870-872
19. Farquhar CM, Birdsall M, Manning P, Mitchell JM, France JT. The prevalence of polycystic ovaries on ultrasound scanning in a population of randomly selected women. Aust N Z J Obstet Gynaecol 1994;34:67-72
20. Koivunen R, Laatikainen T, Tomas C, Huhtaniemi I, Tapanainen J, Martikainen H. The prevalence of polycystic ovaries in healthy women. Acta Obstet Gynecol Scand 1999;78:137-141
21. Chang PL, Lindheim SR, Lowre C, et al. Normal ovulatory women with polycystic ovaries have hyperandrogenic pituitary-ovarian responses to gonadotropin-releasing hormoneagonist testing. J Clin Endocrinol Metab 2000;85:995-1000
22. Carmina E, Wong L, Chang L, et al. Endocrine abnormalities in ovulatory women with polycystic ovaries on ultrasound. Hum Reprod 1997;12:905-909
23. Loucks TL, Talbott EO, McHugh KP, Keelan M, Berga SL, Guzick DS. Do polycystic-appearing ovaries affect the risk of cardiovascular disease among women with polycystic ovary syndrome? Fertil Steril 2000;74:547-552
24. Enskog A, Henriksson M, Unander M, Nilsson L, Brannstrom M. Prospective study of the clinical and laboratory parameters of patients in whom ovarian hyperstimulation syndrome developed during controlled ovarian hyperstimulation for in vitro fertilization. Fertil Steril 1999;71:808-814
25. Koskinen P, Penttila TA, Anttila L, Erkkola R, Irjala K. Optimal use of hormone determinations in the biochemical diagnosis of the polycystic ovary syndrome. Fertil Steril 1996;65:517-522
26. Fox R, Corrigan E, Thomas PA, Hull MG. The diagnosis of polycystic ovaries in women with oligo-amenorrhoea: predictive power of endocrine tests. Clin Endocrinol (Oxf) 1991;34:127-131
27. Legro RS, Driscoll D, Strauss JF III, Fox J, Dunaif A. Evidence for a genetic basis for hyperandrogenemia in polycystic ovary syndrome. Proc Natl Acad Sci U S A 1998;95:14956-14960
28. Nestler JE. Sex hormone-binding globulin: a marker for hyperinsulinemia and/or insulin resistance? [editorial; comment]. J Clin Endocrinol Metab 1993;76:273-274
29. Boots LR, Potter S, Potter D, Azziz R. Measurement of total serum testosterone levels using commercially available kits: high degree of between-kit variability. Fertil Steril 1998;69:286-292
30. Ibanez L, de Zegher F, Potau N. Anovulation after precocious pubarche: early markers and time course in adolescence. J Clin Endocrinol Metab 1999;84:2691-2695
31. Winters SJ, Talbott E, Guzick DS, Zborowski J, McHugh KP. Serum testosterone levels decrease in middle age in women with the polycystic ovary syndrome. Fertil Steril 2000;73:724-729
32. Moran C, Tapia MC, Hernandez E, Vazquez G, Garcia-Hernandez E. Etiological review of hirsutism in 250 patients. Arch Med Res 1994;25:311-314
33. Lobo RA, Goebelsmann U, Horton R. Evidence for the importance of peripheral tissue events in the development of hirsutism in polycystic ovary syndrome. J Clin Endocrinol Metab 1983;57:393-397
34. Carmina E, Koyama T, Chang L, Stanczyk FZ, Lobo RA. Does ethnicity influence the prevalence of adrenal hyperandrogenism and insulin resistance in polycystic ovary syndrome? Am J Obstet Gynecol 1992;167:1807-1812
35. Barth JH. How robust is the methodology for trials of therapy in hirsute women? Clin Endocrinol (Oxf) 1996;45:379-380
36. Holdaway IM, Fraser A, Sheehan A, Croxson MS, France JT, Ibbertson HK. Objective assessment of treatment response in hirsutism. Horm Res 1985;22:253-259
37. Hatch R, Rosenfield RL, Kim MH, Tredway D. Hirsutism: implications, etiology, and management. Am J Obstet Gynecol 1981;140:815-830
38. Lorenzo EM. Familial study of hirsutism. J Clin Endocrinol Metab 1970;31:556-564
39. Derksen J, Moolenaar AJ, Van Seters AP, Kock DF. Semi-quantitative assessment of hirsutism in Dutch women. Br J Dermatol 1993;128:259-263
40. Knochenhauer ES, Hines G, Conway-Myers BA, Azziz R. Examination of the chin or lower abdomen only for the prediction of hirsutism. Fertil Steril 2000;74:980-983
41. Azziz R, Ehrmann D, Legro RS, et al. Troglitazone improves ovulation and hirsutism in the polycystic ovary syndrome: a multicenter, double blind, placebo-controlled trial. J Clin Endocrinol Metab 2001;86:1626-1632
42. Azziz R, Waggoner WT, Ochoa T, Knochenhauer ES, Boots LR. Idiopathic hirsutism: an uncommon cause of hirsutism in Alabama. Fertil Steril 1998;70:274-278
43. Elting MW, Korsen TJ, Rekers-Mombarg LT, Schoemaker J. Women with polycystic ovary syndrome gain regular menstrual cycles when ageing. Hum Reprod 2000;15:24-28
44. Barbieri RL, Ryan KJ. Hyperandrogenism, insulin resistance, and acanthosis nigricans syndrome: a common endocrinopathy with distinct pathophysiologic features. Am J Obstet Gynecol 1983;147:90-101
45. American Diabetic Association. Consensus Development Conference on Insulin Resistance: 5-6 November 1997. Diabetes Care 1998;21:310-314
46. DeFronzo RA, Ferrannini E. Insulin resistance: a multifaceted syndrome responsible for NIDDM, obesity, hypertension, dyslipidemia, and atherosclerotic cardiovascular disease. Diabetes Care 1991;14:173-194
47. Ehrmann DA, Sturis J, Byrne MM, Karrison T, Rosenfield RL, Polonsky KS. Insulin secretory defects in polycystic ovary syndrome: relationship to insulin sensitivity and family history of non-insulin-dependent diabetes mellitus. J Clin Invest 1995;96:520-527
48. Dunaif A, Finegood DT. Beta-cell dysfunction independent of obesity and glucose intolerance in the polycystic ovary syndrome. J Clin Endocrinol Metab 1996;81:942-947
49. Pimenta W, Korytkowski M, Mitrakou A, et al. Pancreatic beta-cell dysfunction as the primary genetic lesion in NIDDM: evidence from studies in normal glucose-tolerant individuals with a first-degree NIDDM relative. JAMA 1995;273:1855-1861
50. Harris MI, Hadden WC, Knowler WC, Bennett PH. Prevalence of diabetes and impaired glucose tolerance and plasma glucose levels in U.S. population aged 20-74 yr. Diabetes 1987;36:523-534
51. Ehrmann DA, Barnes RB, Rosenfield RL, Cavaghan MK, Imperial J. Prevalence of impaired glucose tolerance and diabetes in women with polycystic ovary syndrome. Diabetes Care 1999;22:141-146
52. Falsetti L, Eleftheriou G. Hyperinsulinemia in the polycystic ovary syndrome: a clinical, endocrine, and echographic study in 240 patients. Gynecol Endocrinol 1996;10:319-326
53. Golland IM, Vaughan Williams CA, Shalet SM, Million LH, Elstein M. Lack of predictive value of HbA1 for impaired glucose tolerance in polycystic ovary syndrome. Gynecol Endocrinol 1989;3:229-235
54. Harris MI, Eastman RC, Cowie CC, Flegal KM, Eberhardt MS. Comparison of diabetes diagnostic categories in the U.S. population according to 1997 American Diabetes Association and 1980-1985 World Health Organization diagnostic criteria. Diabetes Care 1997;20:1859-1862
55. DeFronzo RA, Tobin JD, Andres R. Glucose clamp technique: a method for quantifying insulin secretion and resistance. Am J Physiol 1979;237:E214-E223
56. Bergman RN, Prager R, Volund A, Olefsky JM. Equivalence of the insulin sensitivity index in man derived by the minimal model method and the euglycemic glucose clamp. J Clin Invest 1987;79:790-800
57. Norman RJ, Masters SC, Hague W, Beng C, Pannall P, Wang JX. Metabolic approaches to the subclassification of polycystic ovary syndrome. Fertil Steril 1995;63:329-335
58. Knochenhauer ES, Key TJ, Kahsar-Miller M, Waggoner W, Boots LR, Azziz R. Prevalence of the polycystic ovary syndrome in unselected black and white women of the southeastern United States: a prospective study. J Clin Endocrinol Metab 1998;83:3078-3082
59. Diamanti-Kandarakis E, Kouli CR, Bergiele AT, et al. A survey of the polycystic ovary syndrome in the Greek island of Lesbos: hormonal and metabolic profile. J Clin Endocrinol Metab 1999;84:4006-4011
60. Asuncion M, Calvo RM, San Millan JL, Sancho J, Avila S, Escobar-Morreale HF. A prospective study of the prevalence of the polycystic ovary syndrome in unselected Caucasian women from Spain. J Clin Endocrinol Metab 2000;85:2434-2438
61. Talbott E, Guzick D, Clerici A, et al. Coronary heart disease risk factors in women with polycystic ovary syndrome. Arterioscler Thromb Vasc Biol 1995;15:821-826
62. Talbott EO, Guzick DS, Sutton-Tyrrell K, et al. Evidence for association between polycystic ovary syndrome and premature carotid atherosclerosis in middle-aged women. Arterioscler Thromb Vasc Biol 2000;20:2414-2421
63. Legro RS, Kunselman AR, Dunaif A. Prevalence and predictors of dyslipidemia in women with polycystic ovary syndrome. Am J Med 2001;111:607-613
64. Nestler JE, Jakubowicz DJ. Decreases in ovarian cytochrome P450C17-alpha activity and serum free testosterone after reduction of insulin secretion in polycystic ovary syndrome. N Engl J Med 1996;335:617-623
65. Nestler JE, Jakubowicz DJ, Reamer P, Gunn RD, Allan G. Ovulatory and metabolic effects of D-chiro-inositol in the polycystic ovary syndrome. N Engl J Med 1999;340:1314-1320
66. Urbanek M, Legro RS, Driscoll DA, et al. Thirty-seven candidate genes for polycystic ovary syndrome: strongest evidence for linkage is with follistatin. Proc Natl Acad Sci U S A 1999;96:8573-8578
67. Kahsaf-Miller MD, Nixon C, Boots LR, Go RC, Azziz R. Prevalence of polycystic ovary syndrome (PCOS) in first-degree relatives of patients with PCOS. Fertil Steril 2001;75:53-58